CA3058782A1 - Deformable nano-scale vehicles (dnvs) for trans-blood brain barrier, trans-mucosal, and transdermal drug delivery - Google Patents

Deformable nano-scale vehicles (dnvs) for trans-blood brain barrier, trans-mucosal, and transdermal drug delivery Download PDF

Info

Publication number
CA3058782A1
CA3058782A1 CA3058782A CA3058782A CA3058782A1 CA 3058782 A1 CA3058782 A1 CA 3058782A1 CA 3058782 A CA3058782 A CA 3058782A CA 3058782 A CA3058782 A CA 3058782A CA 3058782 A1 CA3058782 A1 CA 3058782A1
Authority
CA
Canada
Prior art keywords
drug delivery
delivery vehicle
nanoscale drug
nanoscale
dnvs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3058782A
Other languages
English (en)
French (fr)
Inventor
Varghese John
Ichiro Nishimura
Naren Subbiah
Jesus Campagna
Patricia R. Spilman
Mohammad Parvez Alam
Original Assignee
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California San Diego UCSD filed Critical University of California San Diego UCSD
Publication of CA3058782A1 publication Critical patent/CA3058782A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/548—Phosphates or phosphonates, e.g. bone-seeking
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA3058782A 2017-04-03 2018-04-02 Deformable nano-scale vehicles (dnvs) for trans-blood brain barrier, trans-mucosal, and transdermal drug delivery Pending CA3058782A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762480924P 2017-04-03 2017-04-03
US62/480,924 2017-04-03
PCT/US2018/025749 WO2018187240A1 (en) 2017-04-03 2018-04-02 Deformable nano-scale vehicles (dnvs) for trans-blood brain barrier, trans-mucosal, and transdermal drug delivery

Publications (1)

Publication Number Publication Date
CA3058782A1 true CA3058782A1 (en) 2018-10-11

Family

ID=63712640

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3058782A Pending CA3058782A1 (en) 2017-04-03 2018-04-02 Deformable nano-scale vehicles (dnvs) for trans-blood brain barrier, trans-mucosal, and transdermal drug delivery

Country Status (6)

Country Link
US (1) US12514929B2 (https=)
EP (1) EP3606557A4 (https=)
JP (2) JP7280624B2 (https=)
CN (1) CN110662532A (https=)
CA (1) CA3058782A1 (https=)
WO (1) WO2018187240A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017087685A1 (en) 2015-11-20 2017-05-26 The Regents Of The University Of California Deformable nano-scale vehicles (dnvs) for trans-blood brain barrier, trans-mucosal, and transdermal drug delivery
CA3058782A1 (en) 2017-04-03 2018-10-11 The Regents Of The University Of California Deformable nano-scale vehicles (dnvs) for trans-blood brain barrier, trans-mucosal, and transdermal drug delivery
CN110251508A (zh) * 2019-05-07 2019-09-20 苏州大学 Nsc-156529作为t-型钙通道拮抗剂的应用
WO2021207273A1 (en) * 2020-04-07 2021-10-14 The Regents Of The University Of California Manufacturing of synthetic exosomes for cns and non-cns delivery of therapeutics
CN111569061A (zh) * 2020-05-06 2020-08-25 吴延恒 一种用于核酸疫苗增强剂的纳米材料
CN114259486B (zh) * 2020-09-16 2024-04-02 香港科技大学 木犀草素及其药物组合物的应用
CN113975397B (zh) * 2021-10-26 2023-08-22 中南大学湘雅三医院 一种基因/小分子化合物纳米递药系统及其制备方法与应用
CN114948852B (zh) * 2022-05-26 2024-05-17 深圳先进技术研究院 一种用于脑部疾病诊断和治疗的微针系统及其制备方法
CN116392449A (zh) * 2023-04-28 2023-07-07 广州医科大学附属第三医院（广州重症孕产妇救治中心、广州柔济医院） 一种橘红素纳米脂质体冻干制剂及其制备方法
CN117551095B (zh) * 2023-11-09 2025-02-07 中国药科大学 一种玫瑰树碱衍生物及其制备方法与应用

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4704355A (en) 1985-03-27 1987-11-03 New Horizons Diagnostics Corporation Assay utilizing ATP encapsulated within liposome particles
WO1991004014A1 (en) 1989-09-21 1991-04-04 Synergen, Inc. Method for transporting compositions across the blood brain barrier
FR2658418B1 (fr) 1990-02-20 1994-09-02 Synthelabo Compositions pharmaceutiques a base de phospholipides.
FR2699818B1 (fr) * 1992-12-24 1995-02-03 Oreal Composition cosmétique ou pharmaceutique contenant en association un polyphénol et un extrait de gingko.
US5858398A (en) 1994-11-03 1999-01-12 Isomed Inc. Microparticular pharmaceutical compositions
US20020048596A1 (en) * 1994-12-30 2002-04-25 Gregor Cevc Preparation for the transport of an active substance across barriers
MXPA00006196A (es) * 1998-10-23 2003-07-21 Idea Ag Metodo para desarrollar, evaluar y utilizar asociaciones de macromoleculas y agregados complejos para obtener mejores tasas de asociacion/desasociacion controlable y carga efectiva.
SI1031347T1 (en) 1999-01-27 2002-10-31 Idea Ag Transnasal transport/immunisation with highly adaptable carriers
GB0118517D0 (en) 2001-07-30 2001-09-19 Mitsubishi Tokyo Pharm Inc Compound
CN1703199B (zh) 2002-10-11 2010-04-28 伊迪亚股份公司 具有增强的可变形性、包含至少三种两亲性物质的聚集物,其用于改善通过半透屏障的转运以及非侵入性药物在体内、具体是通过皮肤的应用
CN1285383C (zh) 2004-07-22 2006-11-22 周翔 亲水亲脂自封闭小体液相核心空化成囊泡的方法及应用
GB0416861D0 (en) 2004-07-29 2004-09-01 Quadrant Drug Delivery Ltd Composition
DE102004057303A1 (de) * 2004-11-26 2006-06-01 Merck Patent Gmbh Stabile Kristallmodifikationen von DOTAP Chlorid
EP1850840A2 (en) * 2005-01-13 2007-11-07 Sirtris Pharmaceuticals, Inc. Novel compositions for preventing and treating neurodegenerative and blood coagulation disorders
JP2006248978A (ja) 2005-03-10 2006-09-21 Mebiopharm Co Ltd 新規なリポソーム製剤
US20110020434A1 (en) * 2005-09-02 2011-01-27 O'halloran Thomas V Nanoparticle arsenic-platinum compositions
CN100453071C (zh) 2006-11-03 2009-01-21 李万忠 白藜芦醇口服多相脂质体及其制备方法
US20090017108A1 (en) 2007-07-11 2009-01-15 Alexander Yuzhakov Liposome compositions for treatment of hepatitis C
US20090082400A1 (en) * 2007-07-31 2009-03-26 Ving Lee Soluble pyrone analogs methods and compositions
JO3076B1 (ar) * 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
WO2009087568A2 (en) * 2008-01-10 2009-07-16 Universidade De Coimbra Compositions comprising antioxidant and mitoprotective flavonoids with neuroprotective properties
CN101474155B (zh) 2009-01-24 2011-03-16 重庆医科大学 注射用肺靶向载药前体脂质体及其使用方法
TR201908314T4 (tr) 2009-02-20 2019-06-21 2 Bbb Medicines B V Glutatyon bazlı ilaç dağıtım sistemi.
SG174287A1 (en) 2009-03-09 2011-10-28 Univ California Single protein nanocapsules for protein delivery with long-term effect
US20110178456A1 (en) 2009-04-03 2011-07-21 The Regents Of The University Of California Assisting transdermal drug delivery by means of tissue freezing, vacuum pressure and photoheating procedures
CN101874763A (zh) 2009-04-29 2010-11-03 上海家化联合股份有限公司 一种白藜芦醇柔性脂质体及其制备方法
WO2010149785A1 (en) 2009-06-26 2010-12-29 Universiteit Gent Cationic liposomes for the delivery of high molecular weight compounds
RU2012103240A (ru) * 2009-07-02 2013-08-10 Ангиокем Инк. Мультимерные пептидные конъюгаты и их применение
EP2394640A1 (en) * 2010-05-21 2011-12-14 MediGene AG Improved liposomal formulations of lipophilic compounds
JP6073783B2 (ja) 2010-06-25 2017-02-01 シャイアー ヒューマン ジェネティック セラピーズ インコーポレイテッド ヘパランｎ−スルファターゼのｃｎｓ送達のための方法および組成物
US10357575B2 (en) 2010-09-24 2019-07-23 Case Western Reserve University Stabilized nanobubbles for diagnostic and therapeutic applications
IT1401882B1 (it) 2010-10-01 2013-08-28 Rosa De Nanoparticelle autoassemblanti per il rilascio di bifosfonati nel trattamento di tumori.
BR112013021731A2 (pt) 2011-02-25 2016-11-01 Univ South Dakota nanopartícula;composição farmacêutica ou cosmética;utilização; método para melhorar a estabilidade de um retinóide;método para melhorar a dispersibilidade de um retinóide; método para proporcinar a libertação sustentada de um retinóide; método para aumentar a penetração na pele de um retinóide;método para aumentar a acumulação de tumor de encapsulamento de droga;método para reduzir a acumulação de drogas em tecidos de rolamento não tumorais; método para reduzir a toxicidade de um retinóide;método para reduzir a irritação da pele classificação de um retinóide aplicado topicamente encapsulante compreendendo uma pluralidade de nanopartículas;método de preparação de uma nanopartícula
EP2688554A2 (en) 2011-03-21 2014-01-29 Gregor Cevc Optimised preparations of highly adaptable aggregates
EP2747768A4 (en) * 2011-08-25 2015-10-21 Cognition Therapeutics Inc COMPOSITIONS AND METHOD FOR THE TREATMENT OF NEURODEEGENERATIVE DISEASES
WO2013059617A1 (en) 2011-10-21 2013-04-25 Ndsu Research Foundation Liposome compositions and methods of use
CN104023793B (zh) 2011-10-31 2017-11-24 马林克罗特有限公司 用于治疗癌症的联合脂质体组合物
EP2874605A1 (en) 2012-07-18 2015-05-27 Onyx Therapeutics, Inc. Liposomal compositions of epoxyketone-based proteasome inhibitors
JP2015524849A (ja) 2012-08-15 2015-08-27 ザ・ユニバーシティ・オブ・シカゴＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃｈｉｃａｇｏ 神経変性疾患に対するエキソソームに基づく治療法
US9943482B2 (en) 2013-02-26 2018-04-17 University Of Louisville Research Foundation, Inc. Milk-derived microvesicle compositions and related methods
CN103446055B (zh) 2013-08-22 2015-02-11 合肥工业大学 三羟基异黄酮脂质纳米体的制备方法
EP3057662A4 (en) 2013-10-17 2017-03-29 Children's Hospital Los Angeles Antibody dependent exosome therapy
WO2015061025A1 (en) 2013-10-22 2015-04-30 Aradigm Corporation Inhaled surfactant-modified liposomal formulations providing both an immediate and sustained release profile
WO2015173133A1 (en) * 2014-05-12 2015-11-19 Chiesi Farmaceutici S.P.A. Formulations and methods of treating alzheimer's disease and other proteinopathies by combination therapy
CN108368487B (zh) 2015-10-01 2022-02-01 渥太华大学 核酸的外泌体包装
CN108779167A (zh) * 2015-10-28 2018-11-09 宾夕法尼亚州大学信托人 鞘内施用腺伴随病毒载体用于基因治疗
WO2017087685A1 (en) 2015-11-20 2017-05-26 The Regents Of The University Of California Deformable nano-scale vehicles (dnvs) for trans-blood brain barrier, trans-mucosal, and transdermal drug delivery
CN105287382A (zh) 2015-12-10 2016-02-03 南昌大学 叶酸-壳聚糖修饰姜黄素纳米脂质体的制备方法
EP3402489B1 (en) 2016-01-15 2021-06-09 Orbsen Therapeutics Limited Sdc-2 exosome compositions and methods of isolation and use
US11073511B2 (en) 2016-02-01 2021-07-27 The Board Of Trustees Of The Leland Stanford Junior University Exosome-Total-Isolation-Chip (ExoTIC) device for isolation of exosome-based biomarkers
US20190112351A1 (en) 2016-04-04 2019-04-18 National Institutes Of Biomedical Innovation, Health And Nutrition Exosome-targeted dna vaccine
US20180028600A1 (en) 2016-07-15 2018-02-01 Korea Institute Of Science And Technology Novel recombinant exosome and use thereof
CN106389137B (zh) 2016-08-29 2019-07-16 杭州素妍化妆品有限公司 一种亚麻籽油脂质体及其制备与应用
US20180067121A1 (en) 2016-09-06 2018-03-08 Nanoco Technologies Ltd. Exosome-conjugated quantum dot nanoparticles and methods of detecting exosomes and cancer using same
US20190231694A1 (en) 2016-10-12 2019-08-01 Agency For Science, Technology And Research Method for lyophilising an exosome
US10800817B2 (en) 2016-12-19 2020-10-13 Morehouse School Of Medicine Compositions and methods for treating diseases by inhibiting exosome release
WO2018118015A1 (en) 2016-12-19 2018-06-28 Morehouse School Of Medicine Compositions and methods for treating diseases by inhibiting exosome release
KR102036051B1 (ko) 2017-02-15 2019-10-24 고려대학교 세종산학협력단 엑소좀 기반의 나노입자 복합체 및 이의 제조방법
CA3058782A1 (en) 2017-04-03 2018-10-11 The Regents Of The University Of California Deformable nano-scale vehicles (dnvs) for trans-blood brain barrier, trans-mucosal, and transdermal drug delivery
US11344627B2 (en) 2017-06-27 2022-05-31 Wisconsin Alumni Research Foundation Dendrimer-exosome hybrid nanoparticles as a delivery platform
WO2019094679A1 (en) 2017-11-10 2019-05-16 The Regents Of The University Of California BRAIN DELIVERY OF THE BACE INHIBITOR SAPPALPHA, ANTIBODIES, OR INHIBITORY RNA's USING SYNTHETIC EXOSOMES (DEFORMABLE NANOVESICLES, DNVs)
WO2019099942A1 (en) 2017-11-17 2019-05-23 Codiak Biosciences, Inc. Compositions of engineered exosomes and methods of loading luminal exosomes payloads
WO2019203706A1 (en) 2018-04-20 2019-10-24 Telefonaktiebolaget Lm Ericsson (Publ) Information decoder for polar codes
WO2019209956A1 (en) 2018-04-25 2019-10-31 University Of Massachusetts Artificial exosome composition and related methods
US20190365653A1 (en) 2018-06-04 2019-12-05 Korea Institute Of Science And Technology Novel recombinant exosome containing hyaluronidase and use thereof
WO2021207273A1 (en) 2020-04-07 2021-10-14 The Regents Of The University Of California Manufacturing of synthetic exosomes for cns and non-cns delivery of therapeutics

Also Published As

Publication number Publication date
JP7280624B2 (ja) 2023-05-24
WO2018187240A1 (en) 2018-10-11
CN110662532A (zh) 2020-01-07
EP3606557A1 (en) 2020-02-12
US20200030457A1 (en) 2020-01-30
JP2023075276A (ja) 2023-05-30
EP3606557A4 (en) 2020-12-16
JP2020515638A (ja) 2020-05-28
US12514929B2 (en) 2026-01-06

Similar Documents

Publication Publication Date Title
US12514929B2 (en) Deformable nano-scale vehicles (DNVS) for trans-blood brain barrier, trans-mucosal, and transdermal drug delivery
US20250295586A1 (en) Deformable nano-scale vehicles (dnvs) for trans-blood brain barrier, trans-mucosal, and transdermal drug delivery
US12539338B2 (en) Nano-enabled immunotherapy in cancer
RU2593367C2 (ru) Основанная на наночастицах, нацеленная на опухоли доставка лекарственных средств
ES2263175T3 (es) Inmunoliposomas que optimizan la internalizacion en celulas diana.
US20200397698A1 (en) Fusogenic liposome-coated porous silicon nanoparticles
Gao et al. Tumor-targeted PE38KDEL delivery via PEGylated anti-HER2 immunoliposomes
AU2018269742A1 (en) Nano-enabled immunotherapy in cancer
CA3098868A1 (en) Carotenoid compositions and uses thereof
CA3157508A1 (en) Nano-enabled immunotherapy in cancer
KR20160085794A (ko) 면역요법용 모듈러 입자
ES2711669A1 (es) Sistemas de liberacion de farmacos de acido polisialico y metodos
US20230398077A1 (en) Silicasome nanocarrier for metal-based drug delivery
Wöll et al. Sortagged anti-EGFR immunoliposomes exhibit increased cytotoxicity on target cells
Gupta et al. Immunoliposomes: a targeted drug delivery system for cancer therapeutics and vaccination
Darji et al. Recent method to improve stability profile, pharmacokinetic and pharmacodynamic properties in anticancer drugs
Swain et al. Systematic review on recent advancements and liposomal technologies to develop stable liposome
Chandra et al. An overview: The novel carrier for vesicular drug delivery system
CN118265543A (zh) 可用于治疗癌症的含有免疫原性细胞死亡(icd)诱导前药的经调配和/或共调配的纳米载剂组合物以及其方法
Johny et al. Liposome assisted drug delivery—A review
Chen et al. Nanoscale self-assembly for delivery of therapeutics and imaging agents
Divi Development and evaluation of brain tumor targeted liposome delivery system for paclitaxel
Kannan Development and Evaluation of Paclitaxel-Loaded Liposomal Formulations for Targeted Drug Delivery to Breast Cancer